Background: While chronic innate and adaptive immune activation are well recognized during HCV and HIV infection, drivers of this process are less clear, and whether the same drivers operate in each infection is unknown. Our data led us to sCD14 and LGALS3BP (90-kDa Mac-binding protein) as potential markers/mediators of immune activation in HCV-HIV infection.
Methods: We measured plasma sCD14, LGALS3BP, IL-6, LBP (LPS-binding protein) and IFABP (intestinal fatty acid binding protein) levels by ELISA in uninfected controls (n=12), HCV infected (n=30), HCV-HIV infected (n=30), and HIV infected (n=30) subjects not on therapy for HCV or HIV. HCV and HCV-HIV infected groups were stratified into low vs. hi APRI subgroups. HIV infected groups were evaluated again at 6 months on ART to determine the contribution of active HIV replication.
Results: In the absence of antiviral therapy HIV infection was associated with elevated plasma sCD14 (p=0.025), IL-6 (p=0.010), IFABP (p=0.05) and LGALS3BP (p<0.0001), while HCV infection was associated with elevated IL-6 (p=0.022) and LGALS3BP (p<0.0001). The latter remained significant in the hi-APRI subgroup for IL-6, and both hi and low APRI subgroups for LGALS3BP. Additionally, sCD14 (p=0.019) and IFABP (p=0.05) levels were greater in HCV hi APRI subjects than uninfected controls. Furthermore, both sCD14 (p<0.0001 and p=0.025) and LGALS3BP (p=0.030 and p<0.0001) levels were greater in HCV-HIV co-infected subjects than both HCV and HIV mono-infected subjects, consistent with contributions from each infection. Furthermore, while LBP was not significantly elevated in either HCV or HIV mono-infection, it was elevated during HCV-HIV co-infection (p=0.005). When evaluating relationships between each marker we observed that sCD14 levels positively correlated with LGALS3BP (p=0.031), IL-6 (p= 0.05) and LBP (p=0.022) during HCV infection, while sCD14 only correlated with LBP (p=0.024) during HIV infection. During HCV-HIV co-infection relationships between sCD14, LBP, and LGALS3BP were similar to those during HCV mono-infection. After initiation of ART for HIV infection, IL-6, LGALS3BP and LBP levels in HIV infected subjects normalized to those of uninfected controls, and those in HCV-HIV infected subjects declined to levels observed in HCV mono infected subjects.
Conclusions: Both HCV infection and consequent liver damage likely drive innate monocyte/macrophage activation by pathways that are overlapping but distinct from HIV infection.